

Conference Program

Saturday, October 17

2:00 p.m.-4:15 p.m. Educational Session
Convention Level
Session Chairperson: Kathleen R. Cho, University of Michigan, Ann Arbor, MI

2:00 p.m. **The origins of ovarian cancer**
Kathleen R. Cho

2:45 p.m. **Genomic classification of ovarian cancer**
David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Australia

3:30 p.m. **Primer on tumor immunology**
Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

4:15 p.m.-5:30 p.m. Break
Florida Ballroom Prefunction

5:30 p.m.-7:30 p.m. Opening Keynote Session
Convention Level
Session Chairperson: Benjamin G. Neel, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

5:30 p.m. **Targeting DNA repair in ovarian cancer therapy**
Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA

6:30 p.m. **One carbon metabolism and cancer**
Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, United Kingdom

7:30 p.m.-9:30 p.m. Opening Reception
Upper Pool Deck

Sunday, October 18

- 7:00 a.m.-8:00 a.m. Continental Breakfast and Mentoring Roundtables**
Plaza International Ballroom G
- 8:00 a.m.-10:00 a.m. Plenary Session 1: DNA Damage and Homologous Recombination**
Convention Level
Session Chairperson: Daniel Durocher, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
- 8:00 a.m. **Regulation of BRCA1- and BRCA2-dependent DNA repair**
Daniel Durocher
- 8:30 a.m. **Targeting checkpoint signaling and DNA repair in ovarian cancer**
Larry M. Karnitz, Mayo Clinic, Rochester, MN
- 9:00 a.m. **PI3K- and PARP-inhibitors for the treatment of women cancers**
Gerburg M. Wulf, Beth Israel Deaconess Medical Center, Boston, MA
- 9:30 a.m. **EMSY impairs DNA damage repair in a phosphorylation-dependent manner***
Petar Jelinic, Memorial Sloan Kettering Cancer Center, New York, NY
- 9:45 a.m. **Identification of germline and somatic alterations in homologous recombination pathway genes in high-grade ovarian carcinomas and response to the PARP inhibitor rucaparib in ARIEL2***
Elizabeth Swisher, University of Washington School of Medicine, Seattle, WA
- 10:00 a.m.-10:30 a.m. Break**
Florida Ballroom Prefunction
- 10:30 a.m.-12:30 p.m. Plenary Session 2: Immunotherapy for Ovarian Cancer**
Convention Level
Session Chairperson: Pamela S. Ohashi, Princess Margaret Cancer Centre, Toronto, ON, Canada
- 10:30 a.m. **Reprogramming T cells for adoptive immunotherapy of ovarian cancer**
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY
- 11:00 a.m. **Regulatory innate lymphoid cells suppress antitumor T cells**
Pamela S. Ohashi
- 11:30 a.m. **Deciphering the immunobiology of ovarian cancer to create effective immunotherapy**
Daniel J. Powell, University of Pennsylvania, Philadelphia, PA
- 12:00 p.m. **Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth***
Ruea-Yea Huang, Roswell Park Cancer Institute, Buffalo, NY
- 12:15 p.m. **Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: Implications for response to immune checkpoint therapy***
Meredith Stone, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

12:30 p.m.-2:30 p.m. Lunch on Own

2:30 p.m.-3:30 p.m. Panel Discussion: Patient Experiences with Decision Making, Including Clinical Trials

Convention Level

Session Moderator: Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Panelists:

Dr. Laura Shawver, The Clarity Foundation, San Diego, CA

Mrs. Diane O'Connor, Ovarian Cancer Alliance of Oregon and Southwest Washington, Vancouver, WA

Ms. Carla Jimenez, Cancer Survivor, St. Petersburg, FL

Dr. James D. Brenton, University of Cambridge, Cambridge, United Kingdom

Dr. Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.-5:30 p.m. Plenary Session 3: Molecular Drivers of Ovarian Cancer (Other than p53)

Convention Level

Session Chairperson: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Australia

3:30 p.m. **Determinants of resistance and response in high-grade serous ovarian cancer**

David D. L. Bowtell

4:00 p.m. **Myc, metabolism, and cancer**

Chi V. Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

4:30 p.m. **The functional genetic architecture of high-grade serous ovarian cancer**

Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada

5:00 p.m. **Identifying potential targets in Cyclin E-amplified tumors***

Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

5:15 p.m. **The long noncoding RNA UCA1 regulates mitochondrial activity and Hippo signaling in ovarian cancer***

Simon Gayther, University of Southern California, Los Angeles, CA

5:30 p.m.-7:30 p.m. Poster Session A and Reception

Plaza International Ballroom D-F

*Short talks from proffered papers

Monday, October 19

- 7:00 a.m.-8:00 a.m. Continental Breakfast and Mentoring Roundtables**
Plaza International Ballroom G
- 8:00 a.m.-10:00 a.m. Plenary Session 4: Non-Serous Ovarian Cancer**
Convention Level
Session Chairperson: David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada
- 8:00 a.m. **Rarer, yet both interesting and relevant: Other ovarian cancers**
David G. Huntsman
- 8:30 a.m. **Endometriosis-related ovarian cancer**
le-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, MD
- 9:00 a.m. **Molecular characterization of mucinous ovarian carcinoma**
Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY
- 9:30 a.m. **Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis***
Michael Anglesio, University of British Columbia, Vancouver, BC, Canada
- 9:45 a.m. **Evidence for extra-ovarian origin and peritoneal metastases that precede ovarian carcinomas in high-grade serous ovarian cancer***
Jeremy Chien, University of Kansas Medical Center, Kansas City, KS
- 10:00 a.m.-10:30 a.m. Break**
Florida Ballroom Prefunction
- 10:30 a.m.-12:45 p.m. Plenary Session 5: Prevention, Screening, Early Diagnostics, and Epidemiology**
Convention Level
Session Chairperson: Nicole D. Urban, Fred Hutchinson Cancer Research Center, Seattle, WA
- 10:30 a.m. **Thinking outside the box: New areas in prevention research**
Shelley S. Tworoger, Harvard School of Public Health, Boston, MA
- 11:00 a.m. **Genetic epidemiology of epithelial ovarian cancer: Recent progress and translational potential**
Thomas A. Sellers, Moffitt Cancer Center and Research Institute, Tampa, FL
- 11:30 a.m. **Biomarkers for risk prediction, screening, and early diagnostics**
Nicole D. Urban
- 12:00 p.m. **Ovarian cancer prevention: Is it time for population screening for BRCA mutations?***
Ian Campbell, Peter MacCallum Cancer Center, East Melbourne, Australia
- 12:15 p.m. **Detection of Müllerian duct carcinomas by lavage of the uterine cavity and mutation analysis: A new concept***
Elisabeth Maritschnegg, Medical University of Vienna, Vienna, Austria
- 12:30 p.m. **Prediagnosis adiposity, physical activity, and ovarian cancer survival***
Adetunji Toriola, Washington University School of Medicine, St. Louis, MO

12:45 p.m.-3:30 p.m. Poster Session B and Lunch
Plaza International Ballroom D-F

3:30 p.m.-5:15 p.m. Plenary Session 6: Molecular Driver of Ovarian Cancer: p53
Convention Level
Session Chairperson: Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m. **Mutant p53 activities in tumor development**
Guillermina Lozano

4:00 p.m. **Clinical implications of p53 mutation in high-grade serous ovarian cancer**
James D. Brenton, University of Cambridge, Cambridge, UK

4:30 p.m. **Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchyme-associated autocrine production of matrix that supports survival and mesothelial intercalation***
Marcin Iwanicki, Harvard Medical School, Boston, MA

4:45 p.m. **A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function in high-grade serous ovarian carcinoma***
Alice Soragni, University of California, Los Angeles, Los Angeles, CA

5:00 p.m. **Exploiting synthetic lethality between the MK2 and p53 pathways with nanotechnology to sensitize ovarian cancer to chemotherapy***
Yi Wen Kong, Massachusetts Institute of Technology, Cambridge, MA

5:15 p.m.-5:30 p.m. Break
Florida Ballroom Prefunction

5:30 p.m.-6:30 p.m. Keynote Plenary Session
Convention Level
Session Chairperson: Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Ovarian cancer screening
Usha Menon, University College of London, London, United Kingdom

*Short talks from proffered papers

Tuesday, October 20

7:00 a.m.-8:00 a.m. Continental Breakfast and Mentoring Roundtables
Plaza International Ballroom G

8:00 a.m.-10:00 a.m. Plenary Session 7: Modeling Systems for Ovarian Cancer

Convention Level

Session Chairperson: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, PA

8:00 a.m. **Developing and deploying experimental models systems towards novel drug discovery in ovarian cancer**

Ronny I. Drapkin

8:30 a.m. **Nutritional intervention for prevention of ovarian cancer in a natural model: The laying hen**

Dale Buck Hales, Southern Illinois University School of Medicine, Carbondale, IL

9:00 a.m. **Role of ARID1A in SWI/SNF chromatin remodeling and ovarian cancer**

Ronald Chandler, Michigan State University College of Human Medicine, Grand Rapids, MI

9:30 a.m. **MYC distal enhancers underlie ovarian cancer susceptibility in the 8q24.21 locus***

Anxhela Gjyshi, Moffitt Cancer Center and Research Institute, Tampa, FL

9:45 a.m. **Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy***

Shengqing Gu, University of Toronto, Toronto, ON, Canada

10:00 a.m.-10:30 a.m. Break

Florida Ballroom Prefunction

10:30 a.m.-12:30 p.m. Plenary Session 8: Ovarian Cancer Tumor Microenvironment

Convention Level

Session Chairperson: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 a.m. **Proteomics reveals a stromal signature of ovarian cancer metastasis**

Ernst R. Lengyel, University of Chicago, Chicago, IL

11:00 a.m. **New directions in targeting the tumor microenvironment**

Anil K. Sood

11:30 a.m. **EGFL6 and angiocrine factor that regulators cancer cell growth and metastasis**

Ronald Buckanovich, University of Michigan, Ann Arbor, MI

12:00 p.m. **Characterization of ascites and tumor-derived ovarian cancer stem-like cells***

Katja Kaipio, University of Turku and Turku University Central Hospital, Turku, Finland

12:15 p.m. **Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment***

Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

12:30 p.m.-12:45 p.m. Closing Remarks

Convention Level

*Short talks from proffered papers